Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

NEW YORK , Sept. 27, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the pricing of its underwritten public offering of 7,058,823 common shares, together with accompanying warrants to purchase 7,058,823 common shares.

MindMed Announces Pricing of Public Offering of Common Shares and Warrants

NEW YORK , Sept. 27, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed") (Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares with accompanying warrants to purchase common shares in an underwritten public offering.

MindMed Announces Proposed Public Offering of Common Shares

First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in healthy subjects Acute effects of equivalent doses will be compared across the following compounds: MDMA, MDA, Lys-MDMA and Lys-MDA NEW YORK , Sept. 20, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the first patient has been dosed in a Phase 1 investigator-initiated study led by MindMed collaborator Prof.

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

Find out why investment bank analysts think this stock is positioned for a six-fold gain.

Wall Street Says This Stock Can Deliver a 543% Return. Should You Listen?

Source: Daniel Patrick Martin / Shutterstock.com MindMed (NASDAQ: MNMD ) stock is in the news Wednesday after the psychedelic medicine company regained Nasdaq compliance. According to a press release from the company, it has satisfied the Nasdaq's minimum bid price listing requirement.

MindMed (MNMD) Stock Regains Nasdaq Compliance

NEW YORK , Sept. 14, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq's minimum bid price listing requirement.

MindMed Announces Compliance with Nasdaq Listing Requirements

MindMed's stock has been moving lower ever since its reverse split last month.

Why Mind Medicine (MindMed) Stock Tumbled This Week

Source: Daniel Patrick Martin / Shutterstock.com MindMed (NASDAQ: MNMD ) stock is on the move Wednesday following positive data from a Phase II clinical trial of MM-120. MM-120 is an LSD treatment in development for patients suffering from anxiety disorders.

MindMed (MNMD) Stock Is Up on Psychedelics News

This Meme Stock Just Did a Huge Reverse Stock Split

Mind Medicine Inc. MNMD, -7.06% (MindMed) shares rose 10% in premarket trades on Thursday after the company said patient dosing in its Phase 2b trial is ongoing and offers a "highly attractive commercial opportunity." The clinical stage biopharmaceutical company that's developing psychedelic medicine to treat brain health disorders said a manuscript that expands on previously reported positive data has been published in the peer-reviewed scientific journal, Biological Psychiatry.

Mind Medicine shares up as Phase 2b studies continue on medical LSD

- Data from University Hospital Basel (UHB) study supports the clinical development of MindMed's proprietary MM-120 product candidate for Generalized Anxiety Disorder ("GAD") – - Patient dosing in Phase 2b trial ongoing for MM-120 in GAD– - MindMed currently owns and retains all clinical data and manufacturing rights for MM-120 and intends to continue broadening its intellectual property portfolio - NEW YORK , Sept. 8, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that the manuscript "Lysergic Acid Diethylamide-Assisted Therapy In Patients With Anxiety With And Without A Life-Threatening Illness A Randomized, Double-Blind, Placebo-Controlled Phase II Study," has been published in the peer-reviewed scientific journal Biological Psychiatry.

MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

NEW YORK , Sept. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will participate virtually at the H.C.

MindMed to Participate in H.C. Wainwright Global Investment Conference

AVEO Pharma

NAPCO Security Technologies

Proto Labs

Clear Secure

Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Napco Security (NSSC), Proto Labs (PRLB), Clear Secure (YOU), AVEO and Mind Medicine (MNMD).

5 Top Stocks to Buy on New Analysts' Coverage

If you can stomach the risks, the reverse split doesn't change much of anything.

After Its Reverse Stock Split, Is Mind Medicine a Buy?

It already has many of the ingredients for memehood.

3 Reasons Why Mind Medicine Might Be the Next Monster Meme Stock

Atai Life Sciences BV

COMPASS Pathways

Cybin

Ameri Holdings

GH Research PLC

Advisorshares Psychedelics ETF

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perceptions.

7 Psychedelics Stocks to Buy for a Big Drug Boom

The consensus price target hints at a 399.3% upside potential for Mind Medicine MindMed Inc. (MNMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 399% Upside in Mind Medicine MindMed Inc. (MNMD): Here's What You Should Know

Mind Medicine (NASDAQ: MNMD ) stock, which had been rising on small trader interest and positive updates, fell nearly 10% as it enacted a 1-for-15 reverse stock split. The stock was also helped by rumors of a short squeeze Aug. 18, which sent it to a post-split high of $19.95 per share.

MindMed (MNMD) Stock Falls After Reverse Stock Split

A 1-for-15 split of Mind Medicine (MindMed) Inc (MNMD) has gone into effect. These are the details.

Mind Medicine (MindMed) (MNMD) Stock: 1-For-15 Split Goes Into Effect

Psychedelics have been in the national spotlight recently and MindMed (NASDAQ: MNMD ) stock has been enjoying the ride. Its mission is to address patient needs through “the therapeutic potential of psychedelics and other novel compounds.

Dear MNMD Stock Fans, Watch This Key Catalyst

- Common shares will begin trading on a split-adjusted basis at market open on August 29, 2022 - NEW YORK , Aug. 26, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its previously announced 1-for-15 reverse share split of the Company's common shares, par value $0.001, became effective after the close of markets on August 26, 2022, with trading expected to begin on a split-adjusted basis on the Nasdaq and the Neo Exchange Inc. (the "NEO") at market open on August 29, 2022. The common shares will continue to trade under the symbols "MNMD" on the Nasdaq and "MMED" on the NEO but are assigned CUSIP number 60255C885 and ISIN number CA60255C8850 following the reverse share split.

MindMed Completes 1-for-15 Reverse Share Split

NEW YORK , Aug. 25, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), for the treatment of Generalized Anxiety Disorder (GAD). "The initiation of our Phase 2b clinical trial, the largest well-controlled clinical trial of LSD ever conducted, represents a major milestone for MindMed and for the many patients suffering from GAD," said Robert Barrow, Chief Executive Officer and Director of MindMed.

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

The company could become a meme stock, which is drawing interest.

Why Shares of Mind Medicine Rose 12.9% on Monday

New York-headquartered Mind Medicine (NASDAQ: MNMD ), sometimes informally known as MindMed, was largely unknown on Wall Street. Recently, however, Mind Medicine garnered attention because one meme-stock trader reportedly bought shares of MNMD stock.

News for Mind Medicine MindMed Stock (MNMD)